ONCT News and Press, Oncternal Therapeutics Inc. From 09/23/22

SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Cantor Oncology, Hematology & HemeOnc Con...

SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the H.C. Wainwright 24th Annual Global Investment...

Summary Today, we are circling back on Oncternal Therapeutics, Inc. for the first time since last October. Despite advancing its pipeline and strong analyst support, the stock currently sells for less than the cash on the company's balance sheet. An investment analysis follows...

Image source: The Motley Fool. Oncternal Therapeutics, Inc. (NASDAQ: ONCT) Q2 2022 Earnings Call Aug 09, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Oncternal Therapeutics, Inc. (ONCT) Q2 2022 Earnings Call Tran...

Oncternal Therapeutics, Inc. (ONCT) Q2 2022 Earnings Conference Call August 9, 2022, 5:00 PM ET Company Participants Richard Vincent - Chief Financial Officer Dr. James Breitmeyer - President and CEO Dr. Salim Yazji - Chief Medical Officer Conference Call P...

Oncternal Therapeutics press release ( NASDAQ: ONCT ): Q2 GAAP EPS of -$0.23 beats by $0.02 . Revenue of $0.2M (-77.3% Y/Y) misses by $0.26M . Extended cash runway guidance to fund operations into the first half of 2024 with $78.9 million in cash and cash equ...

Interim Phase 1/2 results for zilovertamab plus ibrutinib in MCL presented at ASCO 2022, with ORR of 85% and CR rate of 41%, compare favorably to historical single agent ibrutinib data and support moving into Phase 3 Study ZILO-301 Interim data from p53-mutated CLL patients in t...

3 Ways That World Events Cause Penny Stocks Movement When it comes to buying and selling penny stocks, world events are likely the main cause of market movement. Wars, natural disasters, and other geo-political, and economic events can all have a profound effect on both penny stocks a...

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2022 financial results after the U.S. financial mar...

Oncternal Therapeutics ( NASDAQ: ONCT ) on Thursday said it had entered into a clinical trial collaboration with AbbVie ( ABBV ) company Pharmacyclics to support its phase 3 lymphoma study. ONCT stock gained ~9% to $1.22 after hours. As per the terms of the...